aTyr Pharma Announces 1-For-40 Reverse Stock Split, Effective Oct. 28
Benzinga Newsdesk 3 weeks ago
Stock SplitNews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-40, effective at 5:00 p.m. ET on October 28, 2026.
